WealthTrust Axiom LLC Increases Stock Holdings in Pfizer Inc. $PFE

Key Points

• WealthTrust Axiom LLC increased its holdings in Pfizer Inc. by 20.5%, owning a total of 238,105 shares valued at approximately $6.03 million as of the latest SEC filing.
• Other institutional investors also significantly boosted their stakes in Pfizer, with Pacer Advisors Inc. increasing its stake by 856.8% during the same quarter.
• Pfizer reported $14.65 billion in revenue for the last quarter, exceeding analysts' estimates, and declared a quarterly dividend of $0.43 per share, reflecting a 6.7% dividend yield.

WealthTrust Axiom LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,105 shares of the biopharmaceutical company's stock after acquiring an additional 40,457 shares during the period. Pfizer makes up 1.8% of WealthTrust Axiom LLC's holdings, making the stock its 9th largest position. WealthTrust Axiom LLC's holdings in Pfizer were worth $6,034,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its stake in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Nuveen LLC bought a new stake in shares of Pfizer in the 1st quarter worth $389,861,000. Starboard Value LP bought a new stake in shares of Pfizer in the 4th quarter worth $407,730,000. Goldman Sachs Group Inc. raised its stake in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.3%

Shares of Pfizer stock opened at $25.8250 on Monday. The stock's fifty day moving average is $24.70 and its 200-day moving average is $24.39. The firm has a market capitalization of $146.83 billion, a PE ratio of 13.74, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer's payout ratio is currently 91.49%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Wolfe Research boosted their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Jefferies Financial Group boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.